HYPOGLYCEMIC EFFECT OF NOVEL ORAL MICROSPHERES OF INSULIN WITH PROTEASE INHIBITOR IN NORMAL AND DIABETIC RATS

被引:106
作者
MORISHITA, I [1 ]
MORISHITA, M [1 ]
TAKAYAMA, K [1 ]
MACHIDA, Y [1 ]
NAGAI, T [1 ]
机构
[1] HOSHI UNIV,DEPT PHARACEUT,SHINAGAWA KU,TOKYO 142,JAPAN
关键词
INSULIN; MICROSPHERE; ORAL ADMINISTRATION; DIABETIC RAT; PROTEASE INHIBITOR; SERUM GLUCOSE LEVEL;
D O I
10.1016/0378-5173(92)90349-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effectiveness of an oral administration of insulin microspheres (IMS) containing a protease inhibitor was evaluated in normal and diabetic rats. The dosage form is based on the incorporation of insulin with protease inhibitor into polyacrylic polymer (Eudragit L100). These preparations were administered orally with a 20 U/kg insulin dose by force-feeding to rats. Insulin absorption was evaluated by its hypoglycemic effect. IMS without protease inhibitor and with trypsin inhibitor (TI) or chymostatin (CS) produced no marked hypoglycemic response in both groups of rats. A significant continuous hypoglycemic effect was obtained after oral administration of IMS containing aprotinin (AP) or Bowman-Birk inhibitor (BBI) in both normal and diabetic rats when compared with controls. To calculate the relative efficacy, log dose/effect curves for i.v. insulin were obtained in both groups of rats. The efficacy of oral administration, relative to i.v., was assessed by measuring the cumulative percentage of change in serum glucose levels during the experimental period. The efficacy order of four protease inhibitors incorporated into IMS was AP greater-than-or-equal-to BBI > CS = TI. The results suggest that the use of protease inhibitors as pharmaceutical adjuvants for IMS has the advantage of enhancing the efficacy of insulin.
引用
收藏
页码:9 / 16
页数:8
相关论文
共 14 条
  • [1] THE BOWMAN-BIRK INHIBITOR - TRYPSIN-INHIBITOR AND CHYMOTRYPSIN-INHIBITOR FROM SOYBEANS
    BIRK, Y
    [J]. INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, 1985, 25 (02): : 113 - 131
  • [2] PROMOTING EFFECT OF THE NEW CHYMOTRYPSIN INHIBITOR FK-448 ON THE INTESTINAL-ABSORPTION OF INSULIN IN RATS AND DOGS
    FUJII, S
    YOKOYAMA, T
    IKEGAYA, K
    SATO, F
    YOKOO, N
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1985, 37 (08) : 545 - 549
  • [3] BLOOD-GLUCOSE CONTROL AND INSULIN-CLEARANCE IN UNRESTRAINED DIABETIC DOGS PORTALLY INFUSED WITH A PORTABLE INSULIN DELIVERY SYSTEM
    GORIYA, Y
    BAHORIC, A
    MARLISS, EB
    ZINMAN, B
    ALBISSER, AM
    [J]. DIABETOLOGIA, 1980, 19 (05) : 452 - 457
  • [4] KAHN CR, 1990, PHARMACOL BASIS THER, P1463
  • [5] THE ABSORPTION OF INSULIN FROM VARIOUS REGIONS OF THE RAT INTESTINE
    KIDRON, M
    BARON, H
    BERRY, EM
    ZIV, E
    [J]. LIFE SCIENCES, 1982, 31 (25) : 2837 - 2841
  • [6] LEE VHL, 1991, PEPTIDE PROTEIN DRUG, P691
  • [7] LIU JC, 1988, INT J PHARM, V44, P197
  • [8] MORISHITA I, 1991, DRUG DES DELIVERY, V7, P9
  • [9] NOVEL ORAL MICROSPHERES OF INSULIN WITH PROTEASE INHIBITOR PROTECTING FROM ENZYMATIC DEGRADATION
    MORISHITA, M
    MORISHITA, I
    TAKAYAMA, K
    MACHIDA, Y
    NAGAI, T
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1992, 78 (01) : 1 - 7
  • [10] PAQUOT N, 1988, DIABETES METAB, V14, P31